Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series

Osimertinib, as the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended universally as the priority front-line therapeutic for advanced non-small cell lung cancer (NSCLC) carrying EGFR-sensitive mutations. However, patients inevitably acquire drug resistance to osimertinib. Aumolertinib is the second third–generation EGFR-TKI and has been similarly approved as a first-line treatment agent. The present study reports the cases of 3 patients who were challenged with aumolertinib after osimertinib failure. All 3 patients achieved a partial remission. The progression-free survival periods following aumolertinib were 10.0, 11 and 9.0 months (at the time of writing the study). Although the patient in case 2 succumbed to an intracerebral hemorrhage due to hypertension, aumolertinib remained effective as a treatment in cases 1 and 3. The present case series suggests the use of aumolertinib challenge as an optional treatment for patients with metastatic NSCLC harboring EGFR-sensitive mutations after osimertinib failure. The therapeutic strategy of switching from osimertinib to aumolertinib is worth exploring further in the near future.